Cargando…

Glucagon-Like Peptide-1(9-36) Inhibits Chemokine-Induced Migration of Human CD4-Positive Lymphocytes

INTRODUCTION: Inhibitors of dipeptidyl peptidase-IV (DPP-IV), which decrease the degradation of glucose-lowering GLP-1(7-36) to the metabolically inactive GLP-1(9-36), are current new treatment options for patients with type 2 diabetes mellitus, a high-risk population for cardiovascular disease. How...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liberman, Ana, Esser, Melanie, Marx, Nikolaus, Burgmaier, Mathias
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3587602/ https://www.ncbi.nlm.nih.gov/pubmed/23469279 http://dx.doi.org/10.1371/journal.pone.0058445

Ejemplares similares

Correction: Glucagon-Like Peptide-1(9-36) Inhibits Chemokine-Induced Migration of Human CD4-Positive Lymphocytes
por: Liberman, Ana, et al.
Publicado: (2013)

Ivabradine Reduces Chemokine-Induced CD4-Positive Lymphocyte Migration
por: Walcher, Thomas, et al.
Publicado: (2010)

Type 2 diabetes mellitus is associated with a lower fibrous cap thickness but has no impact on calcification morphology: an intracoronary optical coherence tomography study
por: Milzi, Andrea, et al.
Publicado: (2017)

Co-localization of plaque macrophages with calcification is associated with a more vulnerable plaque phenotype and a greater calcification burden in coronary target segments as determined by OCT
por: Burgmaier, Mathias, et al.
Publicado: (2018)

Quantitative Flow Ratio Is Related to Intraluminal Coronary Stenosis Parameters as Assessed with Optical Coherence Tomography
por: Milzi, Andrea, et al.
Publicado: (2021)

Plaque vulnerability of coronary artery lesions is related to left ventricular dilatation as determined by optical coherence tomography and cardiac magnetic resonance imaging in patients with type 2 diabetes
por: Burgmaier, Mathias, et al.
Publicado: (2013)

Allosteric Modulation of the Activity of the Glucagon-like Peptide-1 (GLP-1) Metabolite GLP-1 9–36 Amide at the GLP-1 Receptor
por: Li, Naichang, et al.
Publicado: (2012)

Metabolically-inactive glucagon-like peptide-1(9–36)amide confers selective protective actions against post-myocardial infarction remodelling
por: Robinson, Emma, et al.
Publicado: (2016)

A score to quantify coronary plaque vulnerability in high-risk patients with type 2 diabetes: an optical coherence tomography study
por: Burgmaier, Mathias, et al.
Publicado: (2014)

Computational Peptide Design Cotargeting Glucagon and Glucagon-like Peptide-1 Receptors
por: Vishnoi, Shubham, et al.
Publicado: (2023)

Stability of glucagon-like peptide 1 and glucagon in human plasma
por: Wewer Albrechtsen, Nicolai J, et al.
Publicado: (2015)

Glucagon-like peptide-1 and glucagon-like peptide-2 regulation during human liver regeneration
por: Ammann, Markus, et al.
Publicado: (2023)

High cardiovascular risk of patients with type 2 diabetes is only partially attributed to angiographic burden of atherosclerosis
por: Battermann, Simone, et al.
Publicado: (2020)

GLP-1(28-36)amide, the Glucagon-like peptide-1 metabolite: friend, foe, or pharmacological folly?
por: Taing, Meng-Wong, et al.
Publicado: (2014)

High-Risk Cardiovascular Patients: Clinical Features, Comorbidities, and Interconnecting Mechanisms
por: Schuett, Katharina Andrea, et al.
Publicado: (2015)

Glucagon-Like Peptide-1 and Diabetes
por: Monami, Matteo
Publicado: (2011)

Crystal Structure of Glucagon-like Peptide-1 in Complex with the Extracellular Domain of the Glucagon-like Peptide-1 Receptor
por: Underwood, Christina Rye, et al.
Publicado: (2010)

Glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes
por: Lee, Seungah, et al.
Publicado: (2017)

Glucagon-like peptide 1 and Glucagon-like peptide 2 in relation to osteoporosis in non-diabetic postmenopausal women
por: Montes Castillo, María Cristina, et al.
Publicado: (2019)

Intrinsic calcification angle: a novel feature of the vulnerable coronary plaque in patients with type 2 diabetes: an optical coherence tomography study
por: Reith, Sebastian, et al.
Publicado: (2019)

Coronary plaque composition influences biomechanical stress and predicts plaque rupture in a morpho-mechanic OCT analysis
por: Milzi, Andrea, et al.
Publicado: (2021)

Quantitative Flow Ratio Is Related to Anatomic Left Main Stem Lesion Parameters as Assessed by Intravascular Imaging
por: Milzi, Andrea, et al.
Publicado: (2022)

Coronary microvascular dysfunction as assessed by angiography-derived index of microvascular resistance co-localizes with and may explain the presence of ischemia in stress-cardiac magnetic resonance imaging in the absence of coronary artery disease
por: Milzi, Andrea, et al.
Publicado: (2022)

Regulation of intestinal lipid and lipoprotein metabolism by the proglucagon-derived peptides glucagon like peptide 1 and glucagon like peptide 2
por: Mulvihill, Erin E.
Publicado: (2018)

Acute effects of glucagon‐like peptide‐1, GLP‐1(9–36 amide), and exenatide on mesenteric blood flow, cardiovascular parameters, and biomarkers in healthy volunteers
por: Bremholm, Lasse, et al.
Publicado: (2017)

Dual stack black blood carotid artery CMR at 3T: Application to wall thickness visualization
por: Bornstedt, Axel, et al.
Publicado: (2009)

Quantitative flow ratio (QFR) identifies functional relevance of non-culprit lesions in coronary angiographies of patients with acute myocardial infarction
por: Milzi, Andrea, et al.
Publicado: (2021)

Prognostic irrelevance of plaque vulnerability following plaque sealing in high-risk patients with type 2 diabetes: an optical coherence tomography study
por: Dettori, Rosalia, et al.
Publicado: (2020)

Downregulation of chemokine receptor 9 facilitates CD4(+)CD8αα(+) intraepithelial lymphocyte development
por: Ono, Keiko, et al.
Publicado: (2023)

Glucagon-Like Peptide-1 Gene Therapy
por: Rowzee, Anne M., et al.
Publicado: (2011)

Glucagon-Like Peptide-1 and Diabetes 2012
por: Monami, Matteo, et al.
Publicado: (2012)

Glucagon-like peptide-1 analogues: An overview
por: Gupta, Vishal
Publicado: (2013)

Glucagon-like peptide 1 (GLP-1)
por: Müller, T.D., et al.
Publicado: (2019)

Signalling pathways activated by glucagon-like peptide-1 (7-36) amide in the rat heart and their role in protection against ischaemia
por: Huisamen, Barbara, et al.
Publicado: (2008)

Emetic Response to T-2 Toxin Correspond to Secretion of Glucagon-like Peptide-(17)(–36) Amide and Glucose-Dependent Insulinotropic Polypeptide
por: Zhang, Jie, et al.
Publicado: (2022)

Substance P and Glucagon-like Peptide-1(7-36) Amide Mediate Anorexic Responses to Trichothecene Deoxynivalenol and Its Congeners
por: Jia, Hui, et al.
Publicado: (2022)

Glucagon-Like Peptide 1/Glucagon Receptor Dual Agonism Reverses Obesity in Mice
por: Pocai, Alessandro, et al.
Publicado: (2009)

Glucagon-Like Peptide-1 Receptor Regulates Macrophage Migration in Monosodium Urate-Induced Peritoneal Inflammation
por: Chen, Jun, et al.
Publicado: (2022)

C-Peptide Levels Are Associated With Mortality and Cardiovascular Mortality in Patients Undergoing Angiography: The LURIC study
por: Marx, Nikolaus, et al.
Publicado: (2013)

Lesion Geometry as Assessed by Optical Coherence Tomography Is Related to Myocardial Ischemia as Determined by Cardiac Magnetic Resonance Imaging
por: Dettori, Rosalia, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_udb10vvpjdnsecrdjrbh5t2e12